STE · News · 20261112N

Acquisition / Partnership / Divestiture

STERIS plc · 2026-11-12 · Importance 71 · Surprise 60 · In source text

STERIS priced $1.5 billion of senior notes to help fund its pending acquisition of Xodus Medical. The offering comprises $750 million of 5.650% notes due 2033 and $750 million of 5.875% notes due 2036. Proceeds, term-loan borrowings, and cash are intended to cover the acquisition, related expenses, and general corporate needs; closing was expected around November 24, 2026. The acquisition is described as expanding STERIS's consumables offering.

Key facts

Impact estimates

metricdirectionstageexpectedbasis
cashpositivecommitted+11.9%STERIS priced $1.5 billion in senior notes: $750 million of 5.650% notes due 2033 and $750 million of 5.875% notes due 2036.
liabilitynegativecommitted-11.9%STERIS priced $1.5 billion in senior notes: $750 million of 5.650% notes due 2033 and $750 million of 5.875% notes due 2036.
cashnegativeprobable—STERIS intends to use proceeds from the senior notes, together with term-loan borrowings and cash, to fund its pending acquisition of…
assetspositiveprobable—STERIS intends to use proceeds from the senior notes, together with term-loan borrowings and cash, to fund its pending acquisition of…
liabilitynegativeprobable—STERIS intends to use proceeds from the senior notes, together with term-loan borrowings and cash, to fund its pending acquisition of…